Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 3 pages · Chinese
Release
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Receiving the "Imported Medicinal Materials Approval Document"
- Announcement on External Investment through Participation in the Establishment of a Private Fund
- Announcement on Election of Employee Directors for the 7th Board of Directors
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Completion of 1st Subject Enrollment in Phase Ⅱ Clinical Trials of PZH2107
Later from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Change of Securities Affairs Representative
- Announcement on Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
- Announcement on Progress in Investing in the Regenerative Medicine Fund
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Completion of First Participant Enrollment in the Phase III Clinical Trial of Changji’an Capsules
Follow Zhangzhou Pientzehuang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhangzhou Pientzehuang Pharmaceutical